Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension

Tafluprost is an FP receptor antagonist that has been shown in clinical studies in Europe and Japan to be extremely useful in treating elevated intraocular pressure and glaucoma. The drug is well tolerated and appears to be at least equal in effectiveness and perhaps superior to other protanoids for...

Descripción completa

Detalles Bibliográficos
Autor principal: Schultz, Clyde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661433/
https://www.ncbi.nlm.nih.gov/pubmed/23861619
http://dx.doi.org/10.4137/OED.S4253
_version_ 1782270671743614976
author Schultz, Clyde
author_facet Schultz, Clyde
author_sort Schultz, Clyde
collection PubMed
description Tafluprost is an FP receptor antagonist that has been shown in clinical studies in Europe and Japan to be extremely useful in treating elevated intraocular pressure and glaucoma. The drug is well tolerated and appears to be at least equal in effectiveness and perhaps superior to other protanoids for routine use comparison to be superior to other treatments for the elevated IOP as the side effects and other related symptomology appear to be less, while maintaining a level of pressure control for prolonged periods.
format Online
Article
Text
id pubmed-3661433
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36614332013-07-16 Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension Schultz, Clyde Ophthalmol Eye Dis Review Tafluprost is an FP receptor antagonist that has been shown in clinical studies in Europe and Japan to be extremely useful in treating elevated intraocular pressure and glaucoma. The drug is well tolerated and appears to be at least equal in effectiveness and perhaps superior to other protanoids for routine use comparison to be superior to other treatments for the elevated IOP as the side effects and other related symptomology appear to be less, while maintaining a level of pressure control for prolonged periods. Libertas Academica 2011-01-12 /pmc/articles/PMC3661433/ /pubmed/23861619 http://dx.doi.org/10.4137/OED.S4253 Text en © 2011 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Schultz, Clyde
Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
title Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
title_full Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
title_fullStr Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
title_full_unstemmed Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
title_short Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
title_sort tafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661433/
https://www.ncbi.nlm.nih.gov/pubmed/23861619
http://dx.doi.org/10.4137/OED.S4253
work_keys_str_mv AT schultzclyde tafluprostforthereductionofinterocularpressureinopenangleglaucomaandocularhypertension

Ejemplares similares